和邦生物
(603077)
| 流通市值：181.92亿 | | | 总市值：181.92亿 |
| 流通股本：88.31亿 | | | 总股本：88.31亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 2,566,744,701.12 | 3,061,371,846.19 | 2,784,817,903.44 | 3,064,127,693.33 |
| 应收票据及应收账款 | 1,125,936,161.17 | 1,069,034,187.55 | 1,264,993,483.81 | 977,589,444.12 |
| 应收账款 | 1,125,936,161.17 | 1,069,034,187.55 | 1,264,993,483.81 | 977,589,444.12 |
| 应收款项融资 | 1,671,842,955.2 | 1,935,542,344.58 | 1,303,222,105.98 | 1,050,953,392.62 |
| 预付款项 | 291,427,093.27 | 213,653,426.23 | 235,603,353.58 | 190,934,706.93 |
| 其他应收款合计 | 71,160,979.01 | 31,161,611.82 | 36,983,502.85 | 34,354,614 |
| 存货 | 4,915,503,894.89 | 4,668,904,435.2 | 5,012,592,849.42 | 4,403,120,746.76 |
| 合同资产 | 23,043,247.34 | 27,089,397.78 | 10,667,890.58 | 20,613,115.06 |
| 其他流动资产 | 162,623,323.32 | 128,752,115.85 | 159,233,400.64 | 112,932,579.22 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 10,828,282,355.32 | 11,135,509,365.2 | 10,808,114,490.3 | 9,854,626,292.04 |
| 非流动资产: | | | | |
| 长期股权投资 | 20,270,029.71 | - | - | - |
| 其他权益工具投资 | 339,807,968.23 | 359,757,145.82 | 245,017,889.59 | 207,991,441.31 |
| 其他非流动金融资产 | 459,278,185.83 | 459,278,185.83 | 459,278,185.83 | 459,278,185.83 |
| 固定资产 | 7,890,436,819.61 | 8,073,685,971.44 | 8,265,638,025.09 | 8,471,194,783.73 |
| 在建工程 | 1,881,750,227.09 | 1,663,369,519.2 | 1,492,531,183.12 | 1,173,669,134.85 |
| 使用权资产 | 38,735,361.94 | 33,723,112.19 | 36,282,922.37 | 38,885,540.21 |
| 无形资产 | 2,173,521,410.62 | 2,185,425,067.74 | 2,192,394,385.93 | 2,200,383,425.73 |
| 开发支出 | 155,296,418.97 | 129,942,826.35 | 116,490,024.44 | 100,604,041.73 |
| 商誉 | 1,838,405,543.83 | 1,838,405,543.83 | 1,838,405,543.83 | 1,838,405,543.83 |
| 长期待摊费用 | 3,940,826.18 | 4,245,121.4 | 4,549,416.62 | 4,853,711.84 |
| 递延所得税资产 | 59,149,574.59 | 51,334,435.64 | 53,438,578.32 | 50,383,914.22 |
| 其他非流动资产 | 286,437,958 | 288,233,407.6 | 126,873,930.09 | 142,158,107.53 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 15,147,030,324.6 | 15,087,400,337.04 | 14,830,900,085.23 | 14,687,807,830.81 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 25,975,312,679.92 | 26,222,909,702.24 | 25,639,014,575.53 | 24,542,434,122.85 |
| 流动负债: | | | | |
| 短期借款 | 2,230,354,327.07 | 2,194,229,420.04 | 1,993,053,690.47 | 1,167,634,821.39 |
| 应付票据及应付账款 | 2,748,265,511.61 | 2,829,213,851.1 | 2,408,373,420.15 | 1,877,498,599.01 |
| 其中：应付票据 | 1,288,055,739.4 | 1,279,173,444.36 | 672,485,826.42 | 333,499,537.76 |
| 应付账款 | 1,460,209,772.21 | 1,550,040,406.74 | 1,735,887,593.73 | 1,543,999,061.25 |
| 合同负债 | 75,424,330.17 | 78,426,487.18 | 241,209,337.02 | 95,322,709.43 |
| 应付职工薪酬 | 52,331,882.49 | 48,384,496.45 | 61,611,567.57 | 93,965,298.94 |
| 应交税费 | 42,139,251.77 | 67,763,638.09 | 34,378,377.8 | 64,323,313.36 |
| 其他应付款合计 | 29,626,233.65 | 24,598,603.81 | 15,208,517.77 | 15,065,983.82 |
| 一年内到期的非流动负债 | 577,351,508.21 | 445,536,214.22 | 315,547,883.44 | 346,435,627.74 |
| 其他流动负债 | 6,738,114.43 | 5,775,221.56 | 20,935,753.92 | 9,695,496.97 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 5,762,231,159.4 | 5,693,927,932.45 | 5,090,318,548.14 | 3,669,941,850.66 |
| 非流动负债: | | | | |
| 长期借款 | 604,286,513.58 | 684,654,393.07 | 650,251,532.12 | 431,166,233.69 |
| 租赁负债 | 28,077,669.3 | 21,957,154.31 | 23,585,061.41 | 24,944,196.01 |
| 递延收益 | 69,818,587.68 | 70,753,340.19 | 74,041,319.82 | 75,247,653.83 |
| 递延所得税负债 | 130,109,851.93 | 134,052,696.95 | 126,430,783.6 | 122,751,967.37 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 832,292,622.49 | 911,417,584.52 | 874,308,696.95 | 654,110,050.9 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 6,594,523,781.89 | 6,605,345,516.97 | 5,964,627,245.09 | 4,324,051,901.56 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 8,831,250,228 | 8,831,250,228 | 8,831,250,228 | 8,831,250,228 |
| 资本公积 | 1,153,019,025.48 | 1,141,230,036.47 | 1,124,527,583.61 | 1,124,527,583.61 |
| 减:库存股 | 1,689,756,923.84 | 1,444,939,940.79 | 1,225,552,269.64 | 650,369,774.03 |
| 其他综合收益 | 21,217,804.82 | 34,737,440.25 | 52,990,236.57 | 51,678,261.78 |
| 专项储备 | 20,211,097.81 | 18,571,725.65 | 17,282,508.09 | 14,726,704.82 |
| 盈余公积 | 589,816,235.79 | 589,816,235.79 | 589,816,235.79 | 589,816,235.79 |
| 未分配利润 | 9,838,942,269.45 | 9,807,819,549.19 | 9,643,505,809.4 | 9,613,713,245.31 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 18,764,699,737.51 | 18,978,485,274.56 | 19,033,820,331.82 | 19,575,342,485.28 |
| 少数股东权益 | 616,089,160.52 | 639,078,910.71 | 640,566,998.62 | 643,039,736.01 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 19,380,788,898.03 | 19,617,564,185.27 | 19,674,387,330.44 | 20,218,382,221.29 |
| 负债和股东权益合计 | 25,975,312,679.92 | 26,222,909,702.24 | 25,639,014,575.53 | 24,542,434,122.85 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-20 | 2024-04-20 |
| 审计意见(境内) | | | | 标准无保留意见 |